The clinical potential of radiopharmaceuticals is huge and with 2024 seeing continued multi-billion-dollar investments from pharmaceutical giants such as Novartis, AstraZeneca, BMS and Eli Lilly, advancing your radiopharmaceutical manufacturing processes to keep up with the pace of innovation and ensure trials can progress is crucial.

The 2nd Targeted Radiopharmaceuticals Supply Chain & Manufacturing summit returned as the only industry driven forum dedicated to advancing your radiopharmaceutical production to build reliable supply of products and accelerate trials.

Attendees had the opportunity to discover how to streamline production capabilities and create a stringent supply chain network through uncovering key topics such as, isotope production, radiolabelling, quality control, regulatory considerations and supply network logistics.

Uniting 50+ of the leading C-suite and senior decision-makers in the radiopharmaceutical CMC, regulatory, QC and supply chain field, attendees gained exclusive technical and logistical insights from the likes of from Fusion Pharmaceuticals, Ratio Therapeutics, the IAEA, Telix Pharmaceuticals and many more.

With 2024 already seeing BMS-RayzeBio forced to pause a phase III trial due to an actinium scarcity and AstraZeneca pouring $20M funding into new CDMO player Nucleus RadioPharma to further expand manufacturing capabilities – it is more crucial than ever to lead in supply chain and manufacturing of radiopharmaceuticals to safeguard and stay at the forefront of radiopharmaceutical innovation.